Expiration date: 09/2026

Pharmacokinetics

The bioavailability of mometasone furoate when used in the form of a nasal spray is very low (< 0.1%), and it is practically not detected in blood plasma, even when using a sensitive detection method with a sensitivity threshold of 0.25 pg/ml.

In vitro binding of mometasone furoate to proteins is 98% - 99%, in the concentration range from 5 to 500 ng / ml.

Studies have shown that mometasone furoate is metabolized into several metabolites. No major metabolites were found in plasma. After in vitro incubation, a secondary metabolite 6 was identified?-hydroxy- mometasone furoate. In human liver microsomes, the formation of a metabolite is regulated by cytochrome P-450 3A4 (CYP3A4).

After intravenous administration, the half-life of mometasone furoate from plasma is 5.8 hours. It is excreted from the body in the form of metabolites mainly with bile, and to a small extent with urine.

Pharmacodynamics

Mometasone furoate is a synthetic corticosteroid for topical use with a pronounced anti-inflammatory effect. The local anti-inflammatory effect of mometasone furoate is manifested in doses at which there are no systemic effects.

The mechanism of anti-inflammatory and anti-allergic action of mometasone furoate is associated with its ability to reduce the release of mediators of allergic reactions. It is also a potent inhibitor of the production of Th2 cytokines, IL-4 and IL-5. Momat Rhino nasal spray exhibits anti-inflammatory activity in the early and late stages of an allergic reaction.

Indications for use

• seasonal or year-round allergic rhinitis in adults and children over 6 years of age
• prevention of allergic rhinitis of moderate and severe course (recommended 2-4 weeks before the expected start of the flowering season)
• nasal polyps and related symptoms, including nasal congestion and loss of sense of smell, in patients over 18 years of age

Method of administration and dosage

For nasal use.

Before the first application of Momat Reno, nasal spray, it is necessary to “calibrate” it by pressing the dosing device 10 times. After "calibration", a stereotypical drug supply is established, in which approximately 100 mg of suspension containing 50 micrograms of mometasone furoate (one dose) is released with each press. If the nasal spray has not been used for 14 days or longer, a second "calibration" is necessary.

Shake the spray bottle vigorously before each use.

Seasonal or year-round allergic rhinitis

Adults (including elderly patients) and children 12 years and older: the usual recommended dose is two injections (50 micrograms / dose) into each nostril once a day (total dose 200 mcg). After achieving the therapeutic effect for maintenance therapy, it is advisable to reduce the dose to one injection into each nostril 1 time per day (total dose of 100 mcg).

If the reduction of symptoms of the disease cannot be achieved by using the drug at the recommended therapeutic dose, the daily dose can be increased to a maximum of 4 injections into each nostril 1 time per day (the total daily dose is 400 mcg). After reducing the symptoms of the disease, it is recommended to reduce the dose.

Children aged 6-11 years: the recommended dose is 1 injection (50 mcg) into each nostril 1 time per day (total daily dose of 100 mcg).

The onset of the clinical effect is noted within 12 hours after the first application of the drug.

Nasal polyps and related symptoms, including nasal congestion and loss of sense of smell

Patients from the age of 18 (including elderly patients) - the recommended dose is 2 injections (50 mcg) into each nostril 2 times a day (the total daily dose is 400 mcg). After achieving a clinical effect, it is recommended to reduce the dose to 2 injections into each nostril 1 time per day (the total daily dose is 200 mcg).

Side effects

Often

• irritation at the site of application, burning, itching, sneezing, nosebleed
• ulcerative changes in the nasal mucosa
• headache
• pharyngitis

Rarely

• shortness of breath, bronchospasm

Very rarely

• violation of the sense of smell, taste
• anaphylactic reactions, angioedema
• perforation of the nasal septum

Contraindications

• hypersensitivity to the components of the drug
• nasal spray should not be used in the presence of an untreated local infection of the nasal mucosa
• due to the inhibitory effect of steroids on wound healing, patients who have recently undergone nasal surgery or injury should not use nasal spray in the acute period